Notably, we performed a short-term experiment to single out the effect of IL-6R inhibition with tocilizumab on the cancer stem cells before the therapy caused major differences in overall tumor size which would introduce other confounders (e.g. larger tumors may contain more necrotic cores, increased inflammatory infiltrates..). This evidence concerns the gene IL6R and neoplasm.